Laman UtamaMOLN • NASDAQ
add
Molecular Partners AG
Tutup sebelumnya
$3.75
Julat hari
$3.72 - $3.74
Julat tahun
$3.36 - $7.60
Permodalan pasaran
144.10J USD
Bilangan Purata
3.66K
Nisbah P/E
-
Hasil dividen
-
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (CHF) | Jun 2025info | Perubahan T/T |
|---|---|---|
Hasil | — | — |
Perbelanjaan pengendalian | 3.99J | -10.05% |
Pendapatan bersih | -20.40J | -35.25% |
Margin untung bersih | — | — |
Pendapatan bagi setiap syer | -0.56 | — |
EBITDA | -14.15J | 7.98% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (CHF) | Jun 2025info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 114.49J | -28.05% |
Jumlah aset | 124.25J | -27.17% |
Jumlah liabiliti | 17.59J | 16.89% |
Jumlah ekuiti | 106.66J | — |
Syer tertunggak | 37.39J | — |
Harga kepada buku | 1.32 | — |
Pulangan pada aset | -27.70% | — |
Pulangan pada modal | -30.77% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (CHF) | Jun 2025info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -20.40J | -35.25% |
Tunai daripada operasi | -13.10J | 16.68% |
Tunai daripada pelaburan | 14.97J | 13.85% |
Tunai daripada pembiayaan | -243.00K | 8.99% |
Perubahan bersih dalam tunai | 603.00K | 122.68% |
Aliran tunai bebas | -3.61J | 63.16% |
Perihal
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Diasaskan
2004
Tapak web
Pekerja
153
